...Nanotherapeutics acquired Oscient's Ramoplanin for $500,000 in bankruptcy proceedings. The macrocyclic depsipeptide inhibitor of peptidoglycan biosynthesis...
...of a ramoplanin dimer could aid the design of antibacterial therapies. The antibiotic activity of ramoplanin... ...showed that the N-acyl chain of ramoplanin is essential for its antibiotic activity and helps ramoplanin... ...steps could include using the crystal structure in the rational design of new ramoplanin analogs. Ramoplanin...
...of a ramoplanin dimer could aid the design of antibacterial therapies. The antibiotic activity of ramoplanin... ...showed that the N-acyl chain of ramoplanin is essential for its antibiotic activity and helps ramoplanin... ...steps could include using the crystal structure in the rational design of new ramoplanin analogs. Ramoplanin...
...Phase III trials in about 490 patients each. Patients will receive either 200 mg twice-daily Ramoplanin... ...days. The primary endpoint will be the response rate at the end of the therapy. Ramoplanin... ...peptidoglycan biosynthesis. Oscient Pharmaceuticals Corp. (OSCI), Waltham, Mass. Pfizer Inc. (PFE), New York, N.Y. Product: Ramoplanin...
...submitted an SPA to FDA. The trial was previously reported to start by year end. Ramoplanin... ...the Phase II trial (see BioCentury, Aug. 16). Oscient Pharmaceuticals Corp. (OSCI), Waltham, Mass. Product: Ramoplanin...